Cannabis Law Report

SEPTEMBER 9, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes.

Pharmaceutical 74

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 74

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

WeedAdvisor

SEPTEMBER 24, 2019

GW Pharmaceuticals created the medication after studies showed surprising success treating severe childhood epilepsy, specifically Lennox-Gastaut Syndrome and Dravet Syndrome. But given the amount of CBD needed to treat this condition, patients using marijuana or unregulated hemp products will spend much more. In the U.S.,

Epilepsy 49

Epilepsy CBD Pharmaceutical Access 49

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. Of course, it’s wonderful to see the FDA approve this substance to help those suffering from this rare condition.

Access 98

Access Epilepsy Treatment Conditions 98

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

MassRoots

JANUARY 10, 2019

. “The intention of this legislation is not to generate tax revenue, but rather to provide relief to the thousands of Kentuckian who suffer from conditions that have not responded to traditional medicine,” Rep. Cassie Everett, a woman from Louisville who suffers from epilepsy contacted Rep.

Legalization 111

Legalization Marijuana Epilepsy Legislation 111

MMJ Recs

NOVEMBER 20, 2023

Both THC and CBD have demonstrated analgesic properties, making them valuable for managing chronic pain conditions such as arthritis, fibromyalgia, and cancer-related pain. Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

It seems like the medical research community remains largely divided on the issue, with some insisting that cannabis use contributes to mental health condition diagnoses while others suggesting that people with mental health conditions are inherently drawn to cannabis use. CBD for Anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

The Cannigma

JUNE 1, 2021

Patients can take part if they have a medical condition which has not responded to pharmaceutical drugs. Some of the qualifying health conditions include epilepsy, neuropathic pain, chemotherapy side effects, a need for palliative care, and pain linked to multiple sclerosis, according to France24.

Law 112

Law Epilepsy Programs Patients 112

CannaMD

JULY 14, 2020

Medical marijuana presents itself as a potential solution to this problem: With few side effects, and potential applications in treating a whole host of different conditions , marijuana may be a safer alternative to many of today’s most prescribed medications. WHAT IS POLYPHARMACY? With 35.8% WHO IS AFFECTED MOST?

Marijuana 105

Marijuana Conditions Patients Epilepsy 105

MGC Pharma

DECEMBER 12, 2017

A word from Elad Segev, Manager of Breeding and Cultivation at MGC Pharmaceuticals. It’s also effective in treating patients with refractory epilepsy who experience daily seizures. In fact, MGC Pharma has just released their first product, CannEpil™, a CBD-based medication to help treat patients with refractory epilepsy.

Epilepsy 100

Epilepsy Pharmaceutical Cannabinoids THC 100

Cannabis Law Report

DECEMBER 3, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Phase 2, Placebo-Controlled Clinical Study of Oral Ganaxolone in PCDH19-Clustering Epilepsy (the Violet Study). About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc.

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions. Image by Pfüderi from Pixabay.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Canna Care Docs

SEPTEMBER 18, 2020

To prepare for your appointment you will want to collect your medical records about the condition you wish to treat with medical cannabis. This can be as simple as taking a picture of a prescription bottle you have been given to treat your condition. What Conditions Qualify for Medical Marijuana Cards in Virginia?

Pharmaceutical 98

Pharmaceutical Conditions Patients Oil 98

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

Medical marijuana laws have changed dramatically across the country in recent years, and now cannabis pharmaceuticals appear to be the next big leap forward in cannabis law reform. Epidiolex has received FDA approval to treat Dravet Syndrome and Lennox-Gestaut Syndrome; two very rare forms of epilepsy that manifest in early childhood.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

The Cannigma

JUNE 25, 2022

Poland established a medical cannabis program in 2017, which allows for a range of cannabis products to be prescribed for a range of medical conditions. Patients must have a doctor’s prescription as well as permission from a regional pharmaceutical inspector to obtain cannabis products. Poland and cannabis.

Legalization 108

Legalization Supply Chain Chronic Pain Tincture 108

CannaTech

AUGUST 9, 2018

We are delighted to introduce you to some new friends set to make a big impact on the medical cannabis advocacy scene… the creators of a new documentary called Separating the Strains ; a deeply personal narrative that charts the reality of living with epilepsy, with and without cannabis medication as a treatment option.

Strains 69

Strains Epilepsy Advocacy Medicine 69

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because cannabis is still a schedule 1 drug in the U.S.,

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

CannaTech

APRIL 1, 2020

When I was at Pharmacy School at Sydney University, more than 20 years ago, we learned the pharmaceutical and clinical sciences ranging from the design, synthesis, formulation, dispensing and testing of drugs and the clinical and social aspects of pharmacy. And most especially in these times, cannabis is used effectively to treat anxiety.

Supply Chain 98

Supply Chain Chronic Pain Pharmaceutical Patients 98

Leafwell

MAY 5, 2021

When it comes to caring for diseases and the most vulnerable among us, there are some clear areas where modern pharmaceutical medicine fails, and where medical marijuana succeeds.

Chronic Pain 52

Chronic Pain Epilepsy Law Pharmaceutical 52

Cannabis Law Report

JULY 9, 2021

One of the most popular uses for CBD products is to relieve aches and pains caused by aging, injuries, or medical conditions. Usually, mental health conditions are treated using pharmaceutical drugs, although they can result in side effects such as agitation, drowsiness, headaches, and insomnia. Pain Relief. Stress Relief.

Blood Pressure 105

Blood Pressure CBD Pets Oil 105

Veriheal

MAY 17, 2021

Please don’t further the lie by voting for any form of legalization beyond the pharmaceutical remedies already available under state law.” That is perhaps the biggest lie that is being perpetuated on the Alabama public today. ” State Doctors Oppose Legalization in Alabama.

Legalization 93

Legalization Pharmaceutical Therapy Chronic Pain 93

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. The perception that CBD is a wonder-drug version of cannabis — particularly known for its uses to treat epilepsy — that doesn’t get you high. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

CannaTech

JANUARY 16, 2019

Pharmaceutical grade cannabis is relatively new in parts of the world. The availability of medications for patients varies from country to condition. These estimates vary drastically source to source, which reflects what conditions make a patient eligible for a cannabis-based medicine. million people. million people.

Access 89

Access Patients Pharmaceutical Education 89

Veriheal

SEPTEMBER 22, 2021

If the proposal — which was sponsored by Rules Committee Chairman Bill Rabon (R) — is enacted into law, patients who are diagnosed with a “debilitating medical condition” could legally gain access to medical cannabis in North Carolina. Home cannabis cultivation, on the other hand, would be forbidden.

Legalization 124

Legalization Patients Cultivation Legislation 124

Veriheal

SEPTEMBER 27, 2021

Individuals with this condition have to find ways to deal with the fact that their immune system is attacking the protective sheath of nerve fiber surrounding the nerve cells, putting the body in a state of imbalance that results in muscle spasms, paralysis, disrupted bladder function, mental changes, depression, and even epilepsy.

Treatment 98

Treatment Patients Access Research and Development 98

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. Accessed October 17, 2022. 2021.108514.

CBD 144

CBD Seed-To-Sale Food Access 144

SpeedWeed

JUNE 15, 2021

The British cannabis pharmaceutical company takes home an award that demonstrates how important cannabis has been to the British economy for over 20 years—but also how much it so far has been reserved, as an industry, and as a drug, for the elite. GW Pharmaceuticals was just awarded a so-called “ Queen’s Prize for Innovation.” .

Pharmaceutical 40

Pharmaceutical Chronic Pain Epilepsy Patients 40

Veriheal

NOVEMBER 10, 2020

The experiment will allow participating companies to import cannabis and the companies who wish to participate in the experiment will be obliged to give participants free medical cannabis which has to comply with the pharmaceutical standards and good manufacturing practice. .

Chronic Pain 90

Chronic Pain Pharmaceutical Patients Epilepsy 90

SpeedWeed

JUNE 14, 2021

State officials tasked with overseeing Ohio’s medical marijuana program approved last week the addition of three health conditions that qualify a patient to use cannabis medicinally. Spasticity is a medical condition characterized by prolonged muscle contraction and abnormal muscle tightness. List Of Conditions Reviewed Annually.

Conditions 40

Conditions Programs Therapy Patients 40

Veriheal

JULY 26, 2023

The General Assembly finds that thousands of Georgians have serious medical conditions that can be improved by the medically approved use of cannabis and that the law should not stand between them and treatment necessary for life and health.” And Turnage has hinted that the regulation would be formalized soon.

Oil 98

Oil Patients Access THC 98

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

The Cannigma

MARCH 7, 2022

CBN’s ability to target CB2 receptors, in comparison to THC (which prefers the CB1 receptor), gives it better credibility in treating autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. How much this conversation takes place is not yet well studied and would vary based on many conditions.

THC 139

THC Sleep Clinical Trials Cannabinoids 139

Kind Meds (Cannabis Education Blog)

APRIL 29, 2019

Worsening Conditions. At the age of three, Charlotte tested positive for a gene marker that indicates Dravet syndrome, a rare form of epilepsy that begins in infant or toddlerhood and causes more severe and more frequent seizures over time. In fact, CBD has fewer ill effects than pharmaceutical seizure medications.

Oil 86

Oil Strains Pharmaceutical Research and Development 86

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

Veriheal

JULY 21, 2022

On July 1, the process of procuring pharmaceutical-approved cannabis was simplified for individuals residing across the state, where the first licensed medical marijuana dispensary opened its doors in August 2020. Epilepsy / seizure disorders. Amyotrophic Lateral Sclerosis (ALS) . Cachexia and wasting syndrome. Crohn’s disease.

Access 105

Access Dispensary Patients Programs 105

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We believe that the new data we are revealing today is an extraordinary achievement in the field of pharmaceutical cannabinoids,” said Adam Kaplin, M.D.,

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40